Tuberculosis in Pre-Existing Liver Disease — Complete MD Exam Answer (15 Marks)

INTRODUCTION

SECTION 1: WHY IS LIVER DISEASE A CONCERN IN TB MANAGEMENT?

1.1 Pathophysiological Basis

1.2 Risk Stratification of Liver Disease

⚠️ Key rule (Harrison's 22E): If baseline ALT ≥3× ULN or bilirubin >2× ULN, defer elective ATT and re-evaluate.

SECTION 2: APPROACH & INVESTIGATION

2.1 Clinical Evaluation

• Duration, etiology and severity of liver disease
• Alcohol use (independent hepatotoxic risk factor)
• Prior ATT exposure and tolerance
• Concomitant hepatotoxic drugs (azole antifungals, ART, methotrexate)
• Pregnancy or ≤3 months postpartum (additional hepatic risk factor)

• Jaundice, hepatomegaly, splenomegaly
• Signs of decompensation: ascites, encephalopathy, caput medusae, spider naevi
• Child-Pugh/MELD score assessment

2.2 Baseline Investigations (Mandatory Before ATT)

• Serum ALT, AST, alkaline phosphatase (ALP), GGT
• Total and direct bilirubin
• Serum albumin, INR/PT

• HBsAg, Anti-HCV antibody (reflex HCV RNA if anti-HCV positive)
• HBeAg, HBV DNA (if HBsAg positive)

• Sputum AFB smear and culture (3 specimens)
• GeneXpert MTB/RIF (simultaneous Rifampicin resistance detection)
• Drug sensitivity testing (DST)
• HIV serology (mandatory)
• Chest X-ray; CT thorax if CXR equivocal
• LPA (line probe assay) if MDR-TB suspected
• IGRA or tuberculin skin test (if LTBI)

• Renal function (creatinine, eGFR) — ethambutol dosing
• Complete blood count (CBC)
• Serum uric acid (baseline for pyrazinamide)
• Blood glucose (diabetes is independent ATT-DILI risk factor)
• Ophthalmological assessment (baseline for ethambutol)

• Ultrasound abdomen: liver size, echotexture, splenomegaly, ascites, portal hypertension
• Elastography (fibroscan) or liver biopsy — if cirrhosis severity uncertain
• Upper GI endoscopy: varices (if cirrhosis)

SECTION 3: HEPATOTOXICITY OF INDIVIDUAL ATT DRUGS

Fishman's Pulmonary Diseases, 2022: "PZA can cause severe hepatotoxicity, especially in the elderly and those with pre-existing liver disease." At previously used high doses, hepatotoxicity occurred in up to 15% of patients.

SECTION 4: DEFINITION OF ATT-DILI (Drug-Induced Liver Injury)

Harrison's 22E: "Discontinuation at the onset of hepatitis symptoms reduces the risk of progression to fatal hepatitis."

SECTION 5: MODIFIED ATT REGIMENS IN PRE-EXISTING LIVER DISEASE

5.1 Standard Regimen (for reference)

2HRZE / 4HR — used in patients with no significant liver disease

5.2 Modified Regimens (Severity-Based)

Grade 1: Mild liver disease (compensated, ALT <3× ULN, no jaundice)

• Use standard 2HRZE/4HR but with close monthly monitoring
• Some authorities omit pyrazinamide and extend treatment:

  2HRE / 7HR (9 months total) — PZA-sparing

Grade 2: Moderate liver disease (compensated cirrhosis, chronic active hepatitis, ALT 3–5× ULN)

• Omit PZA — regimen: 9HRE (2HRE + 7HR)
• Alternatively: 2SHE + 6HE — if rifampicin also not tolerated
• Duration extended to 9 months minimum

Grade 3: Severe / Decompensated liver disease (Child-Pugh B/C, ALT >5× ULN, jaundice, acute viral hepatitis)

• Use only 1 or 0 hepatotoxic drugs
• Preferred regimen: 18–24 months of 2SEQ / ongoing SEQ (Streptomycin + Ethambutol + Fluoroquinolone)
• Or: SHRE — streptomycin replaces PZA; rifampicin used cautiously
• Some experts use: REZ without isoniazid if isoniazid is the suspected toxin
• In acute hepatitis: defer all ATT if clinically feasible until hepatitis resolves (ideally 4–6 weeks); use SE + fluoroquinolone as bridge therapy if TB is life-threatening

5.3 Summary Table of Regimen Modification

SECTION 6: MONITORING DURING ATT IN LIVER DISEASE

6.1 Clinical Monitoring (Harrison's 22E, ATS Guidelines)

• Monthly clinical assessment throughout treatment
• Monitor for: nausea, vomiting, jaundice, right upper quadrant pain, dark urine, pale stools, fatigue, pruritus
• Monthly dispensing of drugs facilitates this monitoring

6.2 Biochemical Monitoring (Mandatory in PLD, unlike low-risk patients)

Murray & Nadel's: Monitoring checklist includes baseline LFTs for patients with "viral hepatitis or history of liver disease, HIV, chronic alcohol use, or prior drug-induced liver injury."

6.3 Microbiological Monitoring

• Monthly sputum AFB smears and cultures until confirmed negative
• Culture conversion confirmed at 2 months — critical decision point

SECTION 7: MANAGEMENT OF ATT-DILI WHEN IT OCCURS

Step 1: Stop All Hepatotoxic Drugs

• Immediately stop H, R, Z when DILI criteria met
• Continue safe drugs: Ethambutol + Streptomycin/Fluoroquinolone as bridge to prevent TB progression during washout

Step 2: Investigate

• Rule out other causes: viral hepatitis (acute HAV, HBV flare, HCV), cholecystitis, alcoholic hepatitis
• Repeat LFTs, bilirubin, INR every 1–2 weeks

Step 3: Rechallenge Protocol (Sequential Reintroduction)

1. Rifampicin first (least likely to cause hepatitis) — wait 3–7 days, check LFTs
2. Isoniazid next — wait 3–7 days, check LFTs
3. Pyrazinamide — in most cases, PZA is not re-introduced (not worth the risk)
4. If any drug causes a repeat rise in ALT ≥3× ULN, that drug is the offender — permanently discontinue it and design a PZA-free or INH-free regimen

Harrison's 22E: "With normalization of liver enzymes, R and H may be sequentially reintroduced. With no recurrence of hepatotoxicity, Z is not resumed in many cases."

SECTION 8: SPECIAL SITUATIONS

8.1 TB + Chronic Hepatitis B (HBV)

• Risk of HBV reactivation with rifampicin (immunomodulatory)
• Check HBV DNA before ATT
• If HBV DNA is high: initiate antiviral therapy (tenofovir or entecavir) before or concurrent with ATT
• Monitor HBV DNA and LFTs closely
• Meta-analysis (PMID 36138556): Risk of DILI in HBV-TB co-infection is significantly higher than TB alone

8.2 TB + Chronic Hepatitis C (HCV)

• HCV itself elevates baseline transaminases — makes monitoring interpretation difficult
• Consider HCV treatment (DAAs) first if clinically feasible
• ATT-DILI risk significantly elevated in HCV co-infection
• Rifampicin interactions with some DAAs (e.g., sofosbuvir/ledipasvir) require review

8.3 TB + HIV + Liver Disease (Triple Combination)

• Highest risk of DILI and drug interactions
• Rifampicin powerfully induces CYP3A4 → reduces protease inhibitor (PI) levels by 75–90%
• Use rifabutin (weaker CYP inducer) instead of rifampicin with PI-based ART
• ART should be started within 2 weeks if CD4 ≤50/μL; by 8–12 weeks if CD4 ≥50/μL
• Avoid concomitant hepatotoxic drugs (nevirapine particularly)

8.4 TB + Alcoholic Liver Disease

• Alcohol itself induces CYP2E1 → enhances conversion of isoniazid to toxic metabolites
• Independent risk factor for DILI in TB patients
• Strong counseling on alcohol cessation mandatory
• Consider PZA-free regimen even in mild alcoholic liver disease

8.5 TB + Cirrhosis with Decompensation

• Child-Pugh C: avoid all 3 hepatotoxic drugs if possible
• Use: Streptomycin + Ethambutol + Fluoroquinolone for 18–24 months
• Risk of drug accumulation due to decreased first-pass metabolism and altered protein binding
• Monitor INR frequently (warfarin interaction with rifampicin)
• Ascites: monitor for spontaneous bacterial peritonitis (TB peritonitis may co-exist)

8.6 Latent TB Treatment (LTBI) in Liver Disease

• Isoniazid monotherapy (6–9 months) or Rifampicin (4 months) are standard LTBI regimens
• In liver disease: defer LTBI treatment if ALT ≥3× ULN or bilirubin >2× ULN
• When treated: check ALT and bilirubin at baseline and periodically

SECTION 9: DIRECTLY OBSERVED THERAPY (DOT) & ADHERENCE

• DOT is mandatory in TB + liver disease — critical to detect early toxicity and ensure adherence
• Monthly drug dispensing allows essential clinical monitoring
• Use of video DOT, text message reminders, electronic pillboxes may be considered
• Patient education on symptoms of hepatotoxicity ("stop and seek care" counseling)
• Pyridoxine (Vitamin B6) 25–50 mg/day given with INH to all patients at risk of neuropathy (including those with liver disease/malnutrition); increase to 100 mg/day if peripheral neuropathy develops

SECTION 10: OUTCOMES AND PROGNOSIS

QUICK SUMMARY TABLE: ATT DRUG SAFETY PROFILE IN LIVER DISEASE

CONCLUSION

1. Risk stratification of liver disease severity before starting ATT
2. Regimen modification — reduce hepatotoxic drugs proportionally to hepatic reserve (PZA first to go, then INH if needed)
3. Intensified monitoring — mandatory baseline and monthly LFTs, clinical symptom monitoring, and a clear plan for drug rechallenge following DILI

• Harrison's Principles of Internal Medicine, 22nd Edition (2025) — Ch. 36/186: Tuberculosis Treatment Monitoring Table
• Fishman's Pulmonary Diseases and Disorders, 5th Ed. — Ch. 130: TB Drug Dosing & Adverse Reactions
• Murray & Nadel's Respiratory Medicine — TB Monitoring Checklist
• Chou C et al. (2022). Risk of DILI in chronic hepatitis B and TB co-infection: A systematic review and meta-analysis. J Viral Hepat. [PMID: 36138556]
• Kumar R et al. (2025). Incidence and risk factors of anti-TB drug-induced liver injury in India. Indian J Gastroenterol. [PMID: 39225936]
• Prasad S et al. (2026). Anti-Tubercular Drug-Induced Liver Injury: Current Understanding and Emerging Directions. JGH Open. [PMID: 41561618]
• ATS/CDC/IDSA Official Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016